Stock data
| Market cap. | C$276m |
| Last close | C$3.61 |
| High / Low (52 weeks) | C$6.2 / C$3.4 |
| Stock market listing | TSX, NASDAQ |
| Forecast net cash (C$m) | 30.4 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | (2.43) | (27.8) | (39.43) |
| Relative * | 3.7 | (20.41) | (28.38) |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (C$m) | EBITDA (C$m) | PBT (C$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2010A | 0.0 | (20.0) | (20.0) | (29.5) | N/A | N/A |
| 2011A | 0.0 | (28.7) | (28.3) | (39.9) | N/A | N/A |
| 2012E | 0.0 | (40.9) | (40.9) | (52.4) | N/A | N/A |
| 2013E | 0.0 | (34.9) | (35.0) | (44.8) | N/A | N/A |
Last updated on 19/04/2012
Latest research
Head and neck above
Update | Pharmaceutical & Healthcare | 07/03/2012
Further confirmation
Update | Pharmaceutical & Healthcare | 06/12/2011
Building for success
Review | Pharmaceutical & Healthcare | 20/06/2011
Clinical trials advance
Review | Pharmaceutical & Healthcare | 10/03/2011
Phase III trial now fully funded
Update | Pharmaceutical & Healthcare | 06/12/2010
The game is afoot
Update | Pharmaceutical & Healthcare | 23/06/2010
Steaming into Phase III
Review | Pharmaceutical & Healthcare | 16/04/2010
A viral attack on cancer
Outlook | Pharmaceutical & Healthcare | 06/01/2010
Investment summary
Oncolytics Biotech’s investment case hinges on the outcome of Reolysin’s pivotal Phase III trial in squamous cell carcinoma of the head and neck (SCCHN) which recently completed its first stage recruitment (80 patients). Oncolytics has 12 ongoing clinical trials including Phase II trials in non-small cell lung, pancreatic, melanoma and ovarian cancers, and a Phase I trial in colorectal cancer. Interim data from the pivotal Phase III trial in SCCHN, expected in Q212, could be the trigger to attract a major pharmaceutical licensing partnership that would be required for pivotal studies in the major cancer indications.
Last updated on 23/04/2012
Industry outlook
Oncolytics’s current rivals are the companies developing oncology products in the same therapeutic areas, but there are some interesting viral oncolytic companies, including Jennerex, Genelux and Viralytics, suggesting a new era in cancer treatment. Oncolytics is one of the two leaders in the area, with Amgen the other after its acquisition of BioViex for up to US$1bn.
Last updated on 23/04/2012
Key management
| Brad Thompson, Chairman & CEO |
| Doug Ball, CFO |
Company address
| 210, 1167 Kensington Crescent NW Calgary AB T2N 1X7 Canada +001 403 670 7377 View website |
